A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new ...

The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...

The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...

Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs. Objectives: Medication ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...

Tenofovir alafenamide (Vemlidy) for the initial treatment of chronic hepatitis B may confer modestly higher rates of complete ...

Modern medicine is continually advancing treatment options for many chronic health conditions. For type 2 diabetes and obesity, GLP-1 receptor agonists are medications that may benefit your current ...

We interviewed a physician who provides guidance for patients with diabetes who wish to fast for religious or non-religious reasons. Fasting has been an integral part of religious practices for ...